Capricor Therapeutics
CAPR
30 hedge funds and large institutions have $10.3M invested in Capricor Therapeutics in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 7 closing their positions.
89% more call options, than puts
Call options by funds: $739K | Put options by funds: $390K
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
3% more capital invested
Capital invested by funds: $9.94M → $10.3M (+$329K)
0% more funds holding
Funds holding: 30 → 30 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
0.57% less ownership
Funds ownership: 10.21% → 9.63% (-0.57%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$129K |
| 2 |
VF
Virtu Financial
New York
|
+$72.7K |
| 3 |
Charles Schwab
San Francisco,
California
|
+$58K |
| 4 |
Renaissance Technologies
New York
|
+$32.3K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$24K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$407K |
| 2 |
Millennium Management
New York
|
-$204K |
| 3 |
BlackRock
New York
|
-$193K |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$113K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$109K |
CAPR Hedge Fund Activity: Q1 2023 in Review
30 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q1 2023, worth a combined $10.3M — up 3.3% from $9.94M a quarter earlier.
Fund positioning in CAPR was balanced in Q1 2023: 7 funds opened new positions, 7 closed out, 9 added to existing stakes and 5 trimmed.
The largest buyer was Commonwealth Equity Services, opening a new position worth an estimated $129K. The largest seller was Susquehanna International Group, cutting an estimated $407K.
- 30 institutional investors held Capricor Therapeutics (CAPR) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $10.3M of Capricor Therapeutics stock for Q1 2023, up 3.3% quarter-over-quarter.
- 7 funds opened new Capricor Therapeutics positions in Q1 2023 and 7 closed out, a net change of 0 holders.
- The largest Capricor Therapeutics buyer in Q1 2023 was Commonwealth Equity Services, an estimated $129K added.
- The largest Capricor Therapeutics seller in Q1 2023 was Susquehanna International Group, an estimated $407K sold.
Based on aggregated 13F filings for Q1 2023.